0001792581false00017925812023-09-222023-09-22

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

​

FORM 8-K

​

CURRENT REPORT

​

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): September 22, 2023

​

KIROMIC BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

​

Delaware

    

001-39619

    

46-4762913

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

​

7707 Fannin, Suite 140

Houston, TX, 77054

(Address of principal executive offices) (Zip Code)

​

Registrant’s telephone number, including area code (832) 968-4888

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

​

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of Each Class

    

Trading Symbol(s)

    

Name of Each Exchange on Which Registered

Common Stock, $0.001 par value

KRBP

The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☒

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

​

Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

​

On September 22, 2023, Americo Cicchetti resigned from Kiromic BioPharma, Inc.’s Board of Directors.  Mr. Cicchetti accepted an appointment with the Italian Ministry of Health and is required to resign his existing directorships to avoid any potential conflicts.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​

​

​

Kiromic BioPharma, Inc.

​

​

Date: September 26, 2023

By:

/s/ Pietro Bersani

​

​

Pietro Bersani

​

​

Chief Executive Officer

​

​

​

​

v3.23.3
Document and Entity Information
Sep. 22, 2023
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Sep. 22, 2023
Entity Registrant Name KIROMIC BIOPHARMA, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-39619
Entity Tax Identification Number 46-4762913
Entity Address, Address Line One 7707 Fannin
Entity Address, Adress Line Two Suite 140
Entity Address, City or Town Houston
Entity Address State Or Province TX
Entity Address, Postal Zip Code 77054
City Area Code 832
Local Phone Number 968-4888
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol KRBP
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001792581
Amendment Flag false
Kiromic BioPharma (QB) (USOTC:KRBP)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Kiromic BioPharma (QB) Charts.
Kiromic BioPharma (QB) (USOTC:KRBP)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Kiromic BioPharma (QB) Charts.